APRE Stock Forecast: Aprea Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.23
−52.82% on the day

The median 12-month analyst price target for Aprea Therapeutics, Inc. is $3.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 20 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$7.0M
Ticker Nerd rank
20/ 100
Median analyst target
$3.50
Analysts covering
4
Revenue$0.0
Operating income−$4.0M
Net income−$3.6M
Free cash flow−$3.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−44.1%
1M
−58.5%
YTD
−72.7%
1Y
−79.0%
From 52W high
−81.5%
From 52W low
0.0%
$0.23
$1.26
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Aprea Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
20/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
53
Accruals
47
Growth
44
Volatility
26
Issuance
25
Revisions
23
Value
15
Momentum
13

Quality (53): The business earns solid, repeatable profits on what it owns.

Momentum (13): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

APRE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on APRE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26APREHigh $5.00Median $3.50Low $1.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$1.20
Low
$3.50
Median
$5.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Oct 2026Ladenburg ThalmannInitiatesBuy$2.00
13 Aug 2026WedbushMaintainsOutperform$6.00 → $3.00
14 May 2026WedbushMaintainsOutperform$7.00 → $6.00
7 May 2026OppenheimerInitiatesOutperform$5.00
31 Mar 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026WedbushReiteratesOutperform—
10 Feb 2026WedbushMaintainsOutperform—
29 Jan 2026HC Wainwright & Co.MaintainsBuy—
18 Dec 2025HC Wainwright & Co.MaintainsBuy—
15 Jan 2025HC Wainwright & Co.ReiteratesBuy—
17 Dec 2024HC Wainwright & Co.ReiteratesBuy—
18 Nov 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
13 Aug 2024WedbushReiteratesOutperform—
12 Aug 2024HC Wainwright & Co.ReiteratesBuy—
24 June 2024HC Wainwright & Co.ReiteratesBuy—
17 June 2024HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
27 Mar 2024WedbushMaintainsOutperform—
26 Mar 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for APRE.

Market Radar

This page is one stock. Monday covers all of them.

APRE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

APRE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Aprea Therapeutics, Inc. returned −79.0% against +6.9% for the S&P 500, dividends included.

APRE vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26APRES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

APRE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
914.7×

Cheaper than 1% of US stocks

Price / book
0.1×

Cheaper than 96% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−60.9%

Higher than 19% of US stocks

Return on assets
−35.9%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aprea Therapeutics, Inc. has a market value of $7.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$12.3M.

  • Diluted earnings per share, trailing twelve months: −$1.08.

  • Free cash flow in the twelve months to 30 June 2026: −$12.2M.

  • Shares outstanding: 12.4M.

  • Aprea Therapeutics, Inc. employs 8 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

APRE and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
APREAprea Therapeutics, Inc.$7.0M20
XBIOXenetic Biosciences, Inc.$3.3M28
KPRXKiora Pharmaceuticals, Inc.$3.2M60
NRSNNeurosense Therapeutics Ltd.$3.2M3
LIMNLiminatus Pharma, Inc.$3.4M10
AZTRAzitra, Inc.$3.1M26
SKYESkye Bioscience, Inc.$3.1M50

Take a look at APRE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Aprea Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about APRE

What is the APRE stock price forecast for 2026-2027?

The median 12-month analyst price target for Aprea Therapeutics, Inc. is $3.5, with estimates ranging from $1.2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is APRE stock a buy right now?

Of the 4 analysts covering Aprea Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aprea Therapeutics, Inc. 20 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank APRE?

As at 21 Nov 2026, Aprea Therapeutics, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (53 of 100).

Will APRE stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $3.5, and Ticker Nerd's factor model ranks Aprea Therapeutics, Inc. 20 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the APRE stock forecast for 2030?

No analyst covering Aprea Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.2 to $5 over the next 12 months.

How has APRE stock performed over the past year?

Aprea Therapeutics, Inc. returned -79.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aprea Therapeutics, Inc. do?

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology and biomarker-defined cancers. The company develops targeted cancer therapies designed to exploit DNA damage response and synthetic lethality pathways, aiming to address vulnerabilities in tumor cells while limiting impact on healthy tissue.

Company

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology and biomarker-defined cancers. The company develops targeted cancer therapies designed to exploit DNA damage response and synthetic lethality pathways, aiming to address vulnerabilities in tumor cells while limiting impact on healthy tissue. Its current pipeline centers on investigational small-molecule programs, including APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both being evaluated in clinical development for solid tumor indications. Aprea Therapeutics concentrates on oncology research and drug development for cancers with high unmet medical need, supporting its role in the broader market for targeted and precision medicine therapeutics. The company is headquartered in Doylestown, Pennsylvania.

CEO Dr. Oren Gilad Ph.D. · 8 employees · United States · https://aprea.com